MedPath

Rivipansel

Generic Name
Rivipansel
Drug Type
Small Molecule
Chemical Formula
C58H74N6O31S3
CAS Number
927881-99-0
Unique Ingredient Identifier
4B115V09LB
Background

Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-12-20
Last Posted Date
2020-06-18
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
16
Registration Number
NCT02998099
Locations
🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Phase 1
Completed
Conditions
Moderate Hepatic Impairment
Normal Hepatic Function
Interventions
First Posted Date
2016-08-18
Last Posted Date
2020-07-09
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
16
Registration Number
NCT02871570
Locations
🇺🇸

Orlando Clincial Research Center, Orlando, Florida, United States

A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects

Phase 1
Completed
Conditions
Renal Impairment
Healthy
Interventions
First Posted Date
2016-06-27
Last Posted Date
2020-06-18
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
28
Registration Number
NCT02813798
Locations
🇺🇸

Anaheim Clinical Trials, LLC, Anaheim, California, United States

🇺🇸

Avail Clinical Research, LLC, DeLand, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Phase 3
Terminated
Conditions
Sickle Cell Anemia
Sickle Cell Disease
Sickle Cell Disorders
Pain Crisis
Vaso-occlusive Crisis
Interventions
First Posted Date
2015-05-04
Last Posted Date
2021-02-10
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
154
Registration Number
NCT02433158
Locations
🇺🇸

University of Maryland Medical System, Baltimore, Maryland, United States

🇺🇸

The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins Medicine, Baltimore, Maryland, United States

and more 93 locations

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-08-15
Last Posted Date
2020-06-18
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
27
Registration Number
NCT02217917
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Phase 3
Completed
Conditions
Anemia, Sickle Cell
Interventions
Other: Placebo
First Posted Date
2014-07-10
Last Posted Date
2025-03-11
Lead Sponsor
Biossil Inc.
Target Recruit Count
345
Registration Number
NCT02187003
Locations
🇺🇸

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States

🇺🇸

The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

🇺🇸

Children's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States

and more 135 locations

A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2013-09-13
Last Posted Date
2020-06-18
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
48
Registration Number
NCT01941511
Locations
🇺🇸

Pfizer Investigational Site, San Antonio, Texas, United States

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

Phase 2
Completed
Conditions
Vaso-occlusive Crisis
Sickle Cell Disease
Pain Crisis
Interventions
Drug: Placebo
First Posted Date
2010-05-10
Last Posted Date
2020-05-13
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
81
Registration Number
NCT01119833
Locations
🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

The Johns Hopkins School of Medicine, Baltimore, Maryland, United States

🇺🇸

University of California, Davis Medical Center, Sacramento, California, United States

and more 19 locations

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Phase 1
Completed
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2009-06-02
Last Posted Date
2020-05-11
Lead Sponsor
GlycoMimetics Incorporated
Target Recruit Count
15
Registration Number
NCT00911495
Locations
🇺🇸

Duke Comprehensive Sickle Cell Center, Durham, North Carolina, United States

🇺🇸

Children's Hospital & Research Center Oakland, Oakland, California, United States

🇺🇸

University of California at Davis, CCRC, Sacramento, California, United States

© Copyright 2025. All Rights Reserved by MedPath